✦ LIBER ✦

Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases

✍ Scribed by Christine Y. Lu

Publisher: Springer
Year: 2009
Tongue: English
Weight: 136 KB
Volume: 28
Category: Article
ISSN: 0770-3198
DOI: 10.1007/s10067-009-1102-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Absence of Australia antigen and antibod

Absence of Australia antigen and antibody in patients with rheumatic diseases

✍ Richard S. Panush; Elliot Alpert; Dr. Peter H. Schur 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 2 views

Efficacy of serology driven “test and tr

Efficacy of serology driven “test and treat strategy” for eradication ofH. pyloriin patients with rheumatic disease in the Netherlands

✍ H. T. J. I. de Leest; K. S. S. Steen; W. F. Lems; M. A. F. J. van de Laar; A. M. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 123 KB

The treatment of choice of __H. pylori__ infections is a 7-day triple-therapy with a proton pump inhibitor (PPI) plus amoxicillin and either clarithromycin or metronidazole, depending on local antibiotic resistance rates. The data on efficacy of eradication therapy in a group of rheumatology patient

Quantitative monitoring of cyclin D1 exp

Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma

✍ Helena Brizova; Marketa Kalinova; Lenka Krskova; Marcela Mrhalova; Roman Kodet 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 235 KB

## Abstract In mantle cell lymphoma (MCL), minimal residual disease (MRD) is an indicator of the disease outcome. Quantitative methods used so far do not provide a suitable molecular marker in 30–70% patients with MCL (depending on the technique used). We tested cyclin D1 as a marker for quantitati

Usefulness of18F-fluorodeoxyglucose posi

Usefulness of18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis

✍ Yoshiki Demura; Tatsuro Tsuchida; Daisuke Uesaka; Yukihiro Umeda; Miwa Morikawa; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 233 KB

Investigation of pretreatment prediction

Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs—TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan

✍ Takahisa Furuta; Tomohiko Shimatani; Mitsushige Sugimoto; Shunji Ishihara; Yasuh 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 457 KB

Monitoring the HTLV-1 proviral load in t

Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease

✍ Marina dos Santos Brito Silva Furtado; Rafaela Gomes Andrade; Luiz Cláudio Ferre 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB 👁 2 views

## Abstract Human T‐lymphotropic virus 1 (HTLV‐1) infection is associated with HTLV‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), which affects approximately 5% of carriers. High proviral load is a risk marker for HAM/TSP, although there is an overlap of proviral load levels in peri